Clinical Trials
15 trialsNCT07063745 2026-06-05
MountainTAP-29
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT04267848 2026-06-03
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06096844 2026-06-03
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06194448 2026-06-03
NEOLA
AstraZeneca
Phase 2 Active not recruiting
NCT04736173 2026-06-01
ARC-10
Arcus Biosciences, Inc.
Phase 2 Active not recruiting
NCT05633667 2026-06-01
VELOCITY-Lung
Gilead Sciences
Phase 2 Active not recruiting
NCT06788912 2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT02194738 2026-05-29
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
National Cancer Institute (NCI)
Phase NA Active not recruiting
NCT04092283 2026-05-29
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04310007 2026-05-29
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06731907 2026-05-26
MK-3475-01G
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05800587 2026-05-22
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
Phase 2 Recruiting
NCT06312137 2026-05-22
TroFuse-019
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06704724 2026-05-22
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Terminated
NCT04380636 2026-05-15
MK-7339-012
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting